TY - JOUR
T1 - Polygenic risk for prostate cancer
T2 - Decreasing relative risk with age but little impact on absolute risk
AU - Schaid, Daniel J.
AU - Sinnwell, Jason P.
AU - Batzler, Anthony
AU - McDonnell, Shannon K.
N1 - Funding Information:
This work was supported by the U.S. Public Health Service and National Institutes of Health ( R35 GM140487 ).
Publisher Copyright:
© 2022 American Society of Human Genetics
PY - 2022/5/5
Y1 - 2022/5/5
N2 - Polygenic risk scores (PRSs) for a variety of diseases have recently been shown to have relative risks that depend on age, and genetic relative risks decrease with increasing age. A refined understanding of the age dependency of PRSs for a disease is important for personalized risk predictions and risk stratification. To further evaluate how the PRS relative risk for prostate cancer depends on age, we refined analyses for a validated PRS for prostate cancer by using 64,274 prostate cancer cases and 46,432 controls of diverse ancestry (82.8% European, 9.8% African American, 3.8% Latino, 2.8% Asian, and 0.8% Ghanaian). Our strategy applied a novel weighted proportional hazards model to case-control data to fully utilize age to refine how the relative risk decreased with age. We found significantly greater relative risks for younger men (age 30–55 years) compared with older men (70–88 years) for both relative risk per standard deviation of the PRS and dichotomized according to the upper 90th percentile of the PRS distribution. For the largest European ancestral group that could provide reliable resolution, the log-relative risk decreased approximately linearly from age 50 to age 75. Despite strong evidence of age-dependent genetic relative risk, our results suggest that absolute risk predictions differed little from predictions that assumed a constant relative risk over ages, from short-term to long-term predictions, simplifying implementation of risk discussions into clinical practice.
AB - Polygenic risk scores (PRSs) for a variety of diseases have recently been shown to have relative risks that depend on age, and genetic relative risks decrease with increasing age. A refined understanding of the age dependency of PRSs for a disease is important for personalized risk predictions and risk stratification. To further evaluate how the PRS relative risk for prostate cancer depends on age, we refined analyses for a validated PRS for prostate cancer by using 64,274 prostate cancer cases and 46,432 controls of diverse ancestry (82.8% European, 9.8% African American, 3.8% Latino, 2.8% Asian, and 0.8% Ghanaian). Our strategy applied a novel weighted proportional hazards model to case-control data to fully utilize age to refine how the relative risk decreased with age. We found significantly greater relative risks for younger men (age 30–55 years) compared with older men (70–88 years) for both relative risk per standard deviation of the PRS and dichotomized according to the upper 90th percentile of the PRS distribution. For the largest European ancestral group that could provide reliable resolution, the log-relative risk decreased approximately linearly from age 50 to age 75. Despite strong evidence of age-dependent genetic relative risk, our results suggest that absolute risk predictions differed little from predictions that assumed a constant relative risk over ages, from short-term to long-term predictions, simplifying implementation of risk discussions into clinical practice.
KW - absolute risk prediction
KW - genetic relative risk
KW - weighted Cox regression
UR - http://www.scopus.com/inward/record.url?scp=85129403534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129403534&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2022.03.008
DO - 10.1016/j.ajhg.2022.03.008
M3 - Article
C2 - 35353984
AN - SCOPUS:85129403534
SN - 0002-9297
VL - 109
SP - 900
EP - 908
JO - American journal of human genetics
JF - American journal of human genetics
IS - 5
ER -